1.Erratum: Correction of Figure in the Article “Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)”
Sang Hyun RA ; Euijin CHANG ; Ji-Soo KWON ; Ji Yeun KIM ; JuYeon SON ; Woori KIM ; Choi Young JANG ; Hyeon Mu JANG ; Seongman BAE ; Jiwon JUNG ; Min Jae KIM ; Yong Pil CHONG ; Sang-Oh LEE ; Sang-Ho CHOI ; Yang Soo KIM ; Keun Hwa LEE ; Sung-Han KIM
Journal of Korean Medical Science 2024;39(38):e304-
2.Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Sang Hyun RA ; Euijin CHANG ; Ji-Soo KWON ; Ji Yeun KIM ; JuYeon SON ; Woori KIM ; Choi Young JANG ; Hyeon Mu JANG ; Seongman BAE ; Jiwon JUNG ; Min Jae KIM ; Yong Pil CHONG ; Sang-Oh LEE ; Sang-Ho CHOI ; Yang Soo KIM ; Keun Hwa LEE ; Sung-Han KIM
Journal of Korean Medical Science 2024;39(35):e237-
Background:
The pathophysiological mechanisms underlying the post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) are not well understood.Our study aimed to investigate various aspects of theses mechanisms, including viral persistence, immunological responses, and laboratory parameters in patients with and without PASC.
Methods:
We prospectively enrolled adults aged ≥ 18 years diagnosed with coronavirus disease 2019 (COVID-19) between August 2022 and July 2023. Blood samples were collected at three time-points: within one month of diagnosis (acute phase) and at 1 month, and 3 months post-diagnosis. Following a recent well-designed definition of PASC, PASC patients were defined as those with a questionnaire-based PASC score ≥ 12 persisting for at least 4 weeks after the initial COVID-19 diagnosis.
Results:
Of 57 eligible COVID-19 patients, 29 (51%) had PASC, and 28 (49%) did not. The PASC group had significantly higher nucleocapsid protein (NP) antigenemia 3 months after COVID-19 diagnosis (P = 0.022). Furthermore, several cytokines, including IL-2, IL-17A, VEGF, RANTES, sCD40L, IP-10, I-TAC, and granzyme A, were markedly elevated in the PASC group 1 and/or 3 month(s) after COVID-19 diagnosis. In contrast, the median values of several serological markers, including thyroid markers, autoimmune indicators, and stress-related hormones, were within the normal range.
Conclusion
Levels of NP antigen and of various cytokines involved in immune responses become significantly elevated over time after COVID-19 diagnosis in PASC patients compared to non-PASC patients. This suggests that PASC is associated with prolonged immune dysregulation resulting from heightened antigenic stimulation.
3.Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
Kyung Hwa LEE ; Yong Chan AHN ; Hongryull PYO ; Jae Myoung NOH ; Seung Gyu PARK ; Tae Gyu KIM ; Eonju LEE ; Heerim NAM ; Hyebin LEE ; Jong Mu SUN ; Jin Seok AHN ; Myung Ju AHN ; Keunchil PARK
Cancer Research and Treatment 2019;51(2):769-776
PURPOSE: This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer. MATERIALS AND METHODS: Between February 2004 and December 2016, 127 patients underwent salvage CCRT for LRR. The median radiation therapy (RT) dose was 66 Gy and clinical target volume was to cover recurrent lesion with margin without elective inclusion of regional lymphatics. Majority of patients (94.5%) received weekly platinum-based doublet chemotherapy during RT course. RESULTS: The median follow-up time from the start of CCRT was 25 months. The median survival duration was 49 months, and overall survival (OS) rates at 2 and 5 years were 72.9% and 43.9%. The 2- and 5-year rates of in-field failure-free survival, distant metastasis free survival, and progression free survival were 82.4% and 73.8%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively. Grade ≥ 3 radiation-related esophagitis and pneumonitis occurred in 14 (11.0%) and six patients (4.7%), respectively. On both univariate and multivariate analysis, higher biologically equivalent dose (BED₁₀) (≥ 79.2 Gy₁₀ vs. < 79.2 Gy₁₀; hazard ratio [HR], 0.431), smaller CTV (≤ 80 cm³ vs. > 80 cm³; HR, 0.403), and longer disease-free interval (> 1 year vs. ≤ 1 year; HR, 0.489) were significantly favorable factors for OS. CONCLUSION: The current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular, higher BED₁₀, smaller CTV, and longer disease-free interval were favorable factors for improved survival.
Carcinoma, Non-Small-Cell Lung
;
Disease-Free Survival
;
Drug Therapy
;
Esophagitis
;
Follow-Up Studies
;
Humans
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Pneumonia
;
Recurrence
4.Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome.
Lae Young JUNG ; Sang Rok LEE ; Jin Mu JUNG ; Yi Shik KIM ; Sun Hwa LEE ; Kyoung Suk RHEE ; Jei Keon CHAE ; Dong Hwan LEE ; Dal Sik KIM ; Won Ho KIM ; Jae Ki KO
Korean Circulation Journal 2016;46(2):147-153
BACKGROUND AND OBJECTIVES: Wall shear stress contributes to atherosclerosis progression and plaque rupture. There are limited studies for statin as a major contributing factor on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS). This study investigates the effect of statin on WBV in ACS patients. SUBJECTS AND METHODS: We prospectively enrolled 189 consecutive patients (mean age, 61.3±10.9 years; 132 males; ST-segment elevation myocardial infarction, n=52; non-ST-segment elevation myocardial infarction, n=84; unstable angina n=53). Patients were divided into two groups (group I: previous use of statins for at least 3 months, n=51; group II: statin-naïve patients, n=138). Blood viscosities at shear rates of 1 s-1 (diastolic blood viscosity; DBV) and 300 s-1 (systolic blood viscosity; SBV) were measured at baseline and one month after statin treatment. Rosuvastatin was administered to patients after enrollment (mean daily dose, 16.2±4.9 mg). RESULTS: Baseline WBV was significantly higher in group II ([SBV: group I vs group II, 40.8±5.9 mP vs. 44.2±7.4 mP, p=0.003], [DBV: 262.2±67.8 mP vs. 296.9±76.0 mP, p=0.002]). WBV in group II was significantly lower one month after statin treatment ([SBV: 42.0±4.7 mP, p=0.012, DBV: 281.4±52.6 mP, p=0.044]). However, low-density lipoprotein cholesterol level was not associated with WBV in both baseline (SBV: R2=0.074, p=0.326; DBV: R2=0.073, p=0.337) and after one month follow up (SBV: R2=0.104, p=0.265; DBV: R2=0.112, p=0.232). CONCLUSION: Previous statin medication is an important determinant in lowering WBV in patients with ACS. However, one month of rosuvastatin decreased WBV in statin-naïve ACS patients.
Acute Coronary Syndrome*
;
Angina, Unstable
;
Atherosclerosis
;
Blood Viscosity*
;
Cholesterol
;
Follow-Up Studies
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Lipoproteins
;
Male
;
Myocardial Infarction
;
Prospective Studies
;
Rheology
;
Rupture
;
Rosuvastatin Calcium
5.Inhibition of Melanogenesis by Abietatriene from Vitex Trifolia Leaf Oil.
Hong Gu LEE ; Tae Yoon KIM ; Jung Hoon JEON ; Sang Hwa LEE ; Yoon Ki HONG ; Mu Hyun JIN
Natural Product Sciences 2016;22(4):252-258
Vitex trifolia L. has been used traditionally to treat various illnesses, such as inflammation, headache, migraine, and gastrointestinal infections. We analyzed and evaluated the composition of V. trifolia leaf oil. Based on the results, we isolated abietatriene from V. trifolia leaf oil and investigated the effect of V. trifolia leaf oil and its active compound abietatriene on melanogenesis in B16F10 melanoma cells. They significantly decreased melanin contents and melanogenic factors, such as tyrosinase, TRP-1, TRP-2, and MITF dose-dependently in both protein and mRNA levels. Protein and mRNA expressions were determined by Western blot analysis and quantitative real time RT-PCR. Findings indicate that V. trifolia leaf oil and abietatriene reduce melanogenesis by regulating the expression of melanogenic factors. These results suggest that V. trifolia leaf oil and abietatriene could comprise a useful therapeutic agent for treating hyperpigmentation and used as effective skin-whitening agents.
Blotting, Western
;
Hyperpigmentation
;
Inflammation
;
Melanins
;
Melanoma
;
Migraine Disorders
;
Monophenol Monooxygenase
;
RNA, Messenger
;
Vitex*
6.Clinical Characteristics of Occult HBV Infection and Impact on Treatment Response in Patients with Chronic Hepatitis C.
Sung Soo BYUN ; Jung Woo SHIN ; Myung Kwan KO ; Jung Min HONG ; Kyung Hoon KIM ; Mu Yeol LEE ; Hye Jeong CHOI ; Yoong Ki JEONG ; Bo Ryung PARK ; Neung Hwa PARK
Korean Journal of Medicine 2012;83(6):731-739
BACKGROUND/AIMS: The prevalence of occult HBV infection (OBI) in patients with chronic hepatitis C (CHC) in Korea has not been reported. Additionally, it is unclear whether OBI influences treatment outcome in CHC patients. We investigated the prevalence of OBI and its impact on treatment outcome in patients with CHC. METHODS: Seventy-six patients with CHC were enrolled and treated with pegylated or conventional interferon and ribavirin. Hepatitis B virus (HBV) DNA was detected by nested polymerase chain reaction. RESULTS: Among the 68 patients who completed treatment and follow-up, HBV DNA was detected in serum from nine (13.2%) patients, liver tissue from 10 (14.7%), and serum or liver tissue from 15 (22.1%). OBI was diagnosed in nine (12.7%) control subjects. No difference in the prevalence of OBI between patients with CHC and controls was observed (13.2 vs. 12.0%; p = 0.92). No significant differences in age, sex, genotype 1 frequency, amount of hepatitis C virus RNA, anti-hepatitis B surface antigen/anti-hepatitis B core-IgG seropositivity, staging, or histology grading were observed in patients with or without HBV DNA. Sustained virological response was achieved in 73.3% of patients with OBI and 83.0% without OBI (p = 0.46). CONCLUSIONS: These results demonstrate that a significant proportion of patients with CHC have occult HBV infection and that OBI does not affect treatment outcome in patients with CHC.
DNA
;
Follow-Up Studies
;
Genotype
;
Hepacivirus
;
Hepatitis B virus
;
Hepatitis C, Chronic
;
Hepatitis, Chronic
;
Humans
;
Interferons
;
Korea
;
Liver
;
Prevalence
;
Ribavirin
;
RNA
;
Treatment Outcome
7.Evidence of Lung Function for Stratification of Cardiovascular Disease Risk.
Hwa Mu LEE ; Steven T TRUONG ; Nathan D WONG
Korean Circulation Journal 2011;41(4):171-174
Among adults in the United States, the prevalence of reduced lung function including obstructive and restrictive lung disease is about 20%, representing an over 40 million adults. Persons with reduced lung function often demonstrate chronic systemic inflammation, such as from elevated levels of C-reactive protein. Substantial data suggests that inflammation may have a significant role in the association between reduced lung function and cardiovascular disease (CVD); however, how reduced lung function predicts CVD as risk modification remains largely unknown. Poor lung function has been shown to be a better predictor of all-cause and cardiac-specific mortality than established risk factors such as serum cholesterol, and CVD is the leading cause of mortality among those with impaired lung function. The exact mechanism of atherosclerosis is not clear, but persistent low grade inflammation is considered as one of the culprits in clot formation. The initial presentation of coronary heart disease is either myocardial infarction or sudden death in approximately half of the individuals. Unfortunately, conventional risk factor assessment predicts only 65-80% of future cardiovascular events, leaving many middle-aged and older individuals to manifest a major cardiovascular event despite being classified low risk by the Framingham risk estimates.
Adult
;
Atherosclerosis
;
C-Reactive Protein
;
Cardiovascular Diseases
;
Cholesterol
;
Coronary Disease
;
Death, Sudden
;
Humans
;
Inflammation
;
Lung
;
Lung Diseases
;
Myocardial Infarction
;
Prevalence
;
Respiratory Function Tests
;
Risk Factors
;
United States
8.Epidemiology of Erectile Dysfunction in one Korean Rural Community.
Jin Pyo HONG ; Hae Cheol SONG ; Mu Song LEE ; Chang Hwa LEE ; Jun Ho AHN ; Oh Su HAHN ; Tae Young AHN ; Seong Yoon KIM
Journal of Korean Neuropsychiatric Association 2005;44(6):708-713
OBJECTIVES: The purpose of this study was to investigate the prevalence of erectile dysfunction (ED) in a rural area of Korea and to examine the relationship between the prevalence and correlates of subjects. METHOD: This study was done as a part of the chronic disease survey of rural area by the Asan Foundation. Among 30 years or older population from Jung Eup, a rural area of Korea, 711 male subjects were sampled using a cluster probability sampling method. Trained interviewers visited and interviewed subjects aged 30 years or older with a structured interview. ED was categorized as 'none', 'mild', 'moderate', or 'severe' according to the ability to 'attain and/or maintain an erection satisfactory for sexual intercourse'. Response rate was 54.3% (N=386). RESULTS: The age weighted prevalence of ED was 27.2% (minimal 14.1%, moderate 7.6%, severe 5.5%). Prevalence and severity increased with age. Liver disease and underweight were significantly (p<0.05) associated with ED. Smoking seemed to be correlated with ED, but did not reach statistically significant level. CONCLUSION: ED was highly prevalent in the rural community of Korea. Medical, sociodemographic, and lifestyle variables associated with ED may alert physicians to patients at risk for ED and offer insight to its etiology.
Chronic Disease
;
Chungcheongnam-do
;
Epidemiology*
;
Erectile Dysfunction*
;
Humans
;
Korea
;
Life Style
;
Liver Diseases
;
Male
;
Prevalence
;
Risk Factors
;
Rural Population*
;
Smoke
;
Smoking
;
Thinness
9.Secretion of TNF-alpha via Proteinase-Activated Receptor-2 in Human Astrocyte Cell Line.
Mi Sun KIM ; Jin Ah KIM ; Ok Hwa KANG ; Ok Seon BAEK ; Jae Young UM ; Jin Mu YI ; Ki Jung YUN ; Hyung Min KIM ; Young Mi LEE
Korean Journal of Pathology 2003;37(3):159-165
BACKGROUND: Proteinase-activated receptor 2 (PAR2) is cleaved, and it is activated by trypsin or mast cell tryptase. PAR2 plays an important role in inflammation. The aim of this study is to examine the potential of PAR2 agonists to modulate TNF-alpha secretion from the human astrocytoma cell line CCF-STTG1. METHODS: PAR2 expression in CCF-STTG1 was examined using reverse transcriptase polymerase chain reaction and immunocytochemistry. The potential of PAR2 agonists to modulate TNF-alpha secretion from CCF-STTG1 was examined by enzyme-linked immunosorbent assays. RESULTS: CCF-STTG1 expresses PAR2. PAR2 agonists such as trypsin, mast cell tryptase, and activating peptide SLIGKV-NH2 (corresponding to the PAR2 tethered ligand) directly signal CCF-STTG1 to induce the secretion of TNF-alpha but not in the case of the soybean trypsin inhibitor (SBTI) or VKGILS-NH2 (control peptide). Furthermore, the secretion of TNF-alpha was significantly reduced in CCF-STTG1 cells pre-treated with either 50 microM PD98059 (mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor) or 1 microM SB203580 (p38 MAPK inhibitor) 30 min before trypsin stimulation. CONCLUSIONS: These results show that trypsin may induce TNF-alpha secretion through the activation of MEK and p38 MAPK via PAR2 in astrocytoma cell line CCF-STTG1.
Astrocytes*
;
Astrocytoma
;
Cell Line*
;
Enzyme-Linked Immunosorbent Assay
;
Humans*
;
Immunohistochemistry
;
Inflammation
;
p38 Mitogen-Activated Protein Kinases
;
Phosphotransferases
;
Reverse Transcriptase Polymerase Chain Reaction
;
Soybeans
;
Trypsin
;
Tryptases
;
Tumor Necrosis Factor-alpha*
10.Protective Effect of PKC and Nitric Oxide Affecting Taxol-Induced Cytotoxicity in C6-Gial Cells.
Heung Jae LEE ; Sang Chul KWAN ; Han Sol LEE ; Jung Mu HUR ; Deok Hwa CHOI ; Jay Min OH ; Jeong Joong KIM ; Min Kyu CHOI ; Yeun Tai CHUNG
Korean Journal of Anatomy 2003;36(5):363-370
Paclitaxel (Taxol) is known as effective drug for inhibition of cell cycle encouraging in human cancer cells. This drug named an antimicrotubule agent which simulate the mitotic arrest towards an apoptosis. The influence of phorbol 12 myristate 13 acetate (PMA) activated protein kinase C (PKC) and nitric oxide (NO) on taxol-induced apoptosis, is poorly understood. To investigate the effects of PMA and NO on the signal transduction in taxol-induced apoptosis in C6-glial cells, the viability and caspase-3 activity of C6-glial cells were analyzed. Pretreatement with PKC activatior (PMA) protected taxol-induced cell death in C6-glial cells, by inhibited caspases-3 activity. On the other hand, the taxol-induced apoptosis was highly enhanced by sodium nitroprusside (SNP) and lipopolysaccharide (LPS), as NO activator. These results suggest that PMA strongly blocks the apoptotic effect of taxol, while nitric oxide has no protective effects in the process of toxol-induced apoptosis in C6-glial cells.
Apoptosis
;
Caspase 3
;
Cell Cycle
;
Cell Death
;
Hand
;
Humans
;
Myristic Acid
;
Nitric Oxide*
;
Nitroprusside
;
Paclitaxel
;
Protein Kinase C
;
Signal Transduction

Result Analysis
Print
Save
E-mail